Tigecycline-induced acute pancreatitis: about two cases and review of the literature.
Tigecycline (formerly CAR-936, Tygacyl) is the first glycylcycline antibiotic available for clinical use. It has an expanded broad-spectrum antibiotic activity. Phase III studies have identified gastrointestinal side-effects, especially nausea and vomiting, as the most common adverse events. Few cases of acute pancreatitis (AP) have been described in the literature. We report two new cases of mild tigecycline-induced pancreatitis. Tigecycline was given for soft-tissue infection in both cases. Symptoms such as nausea, vomiting and mostly abdominal pain occurred within 5 days after starting Tigecycline. Pancreatic enzymes elevation occurred five to six days after initiation of treatment, and resolved within a week after drug-discontinuation. Diagnosis of mild pancreatitis was confirmed after performing CT-Scan of the abdomen in both cases. We take this opportunity to review the literature about this potentially serious side-effect induced by tigecycline.
Department of Internal Medecine and Infectious Diseases, Cliniques Universitaires St Luc,
J-C
JC
Marot
S
S
Jonckheere
H
H
Munyentwali
L
L
Belkhir
B
B
Vandercam
J C
JC
Yombi
D000681:Amylases / Q000032:analysis; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D006801:Humans; D008049:Lipase / Q000032:analysis; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000009:adverse effects / Q000031:analogs & derivatives*; D010195:Pancreatitis / Q000139:chemically induced*; D018461:Soft Tissue Infections / Q000188:drug therapy; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008049:Lipase; D000681:Amylases; D008911:Minocycline